Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure Trial

Majani, Giuseppina; Giardini, Anna; Opasich, Cristina; Glazer, Robert; Hester, Allen; Tognoni, Gianni; Cohn, Jay N.; Tavazzi, Luigi

doi:10.1016/j.cardfail.2004.11.004

Cited by 52 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent demonstration that HRQL scores in heart failure patients are related with the severity of the disease [7,8], have prognostic value [10][11][12] and are also modified by treatment with several drugs (ACEIs, BBs, ARBs) [23][24][25] has aroused interest to evaluate if, in addition to the usual clinical variables, they can be used to identify patients who are at special risk for suffering an event (death/hospitalisation) and thus are candidates for closer follow-up and more intensive treatment. However, most of the available evidence comes from clinical trials or studies carried out in the hospital setting in patients with acute or severe disease.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: The INCA study

Rivas

Permanyer-Miralda

Brotons³

et al. 2008

Qual Life Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: The INCA study

Rivas

Permanyer-Miralda

Brotons³

et al. 2008

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…However, this intervention group was relatively limited with 275 patients, including a final assessment available for only 24 patients. In the Val-HefT study, 14 patients also showed early modest improvement at 4 months (2.5 points), and then a tendency to worsen progressively; at 2 years of follow-up the mean scores were similar to baseline Renal failure was defined as a creatinine clearance rate ,60 mL/min; anaemia was defined as haemoglobin ,12 g/dL. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; HF t, heart failure duration from onset; LVEF, left ventricular ejection fraction; MLWHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; PVD, peripheral vascular disease; QoL, quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…No significant differences were found in demographic and clinical characteristics between those patients who completed the questionnaires and those who did not. QoL scores decreased during the first year [29 at baseline (P 25 -P 75 16 -43) vs. 15 (P 25 -P 75 [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]) at 1 year, P , 0.001], which was tempered, yet remained significant, up to 5 years [12 (P 25 -P 75 7-23) at 3 years vs. 10 (P 25 -P 75 5-21) at 5 years, P ¼ 0.012; Figure 3]. The worse the initial QoL, the greater the improvement observed during the first year.…”

Section: Quality Of Life Monitoringmentioning

confidence: 99%

Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value

Lupón

Gastelurrutia

Antonio

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

AimsHeart failure (HF) is a chronic condition that typically affects a patient's quality of life (QoL). Little is known about long-term QoL monitoring in HF. This study aimed to evaluate the temporal changes and prognostic value of QoL assessment in a real-life cohort of HF patients. Methods and resultsThe Minnesota Living with Heart Failure Questionnaire was used to monitor QoL at baseline and at 1, 3, and 5 years for 1151 consecutive patients {71.7% men, median age 69 years [25th-75th percentiles (P 25 -P 75 ) 59-76]} in an HF unit. Follow-up for prognosis assessment was extended to 6 years. The number of answered questionnaires was 1151 at baseline, 746 at 1 year, 268 at 3 years, and 240 at 5 years. QoL scores showed a steep decrease (indicating QoL improvement) during the first year [29 (P 25 -P 75 16 -43) at baseline vs. 15 (P 25 -P 75 8-27) at 1 year, P , 0.001], which was tempered, yet significant up to 5 years [12 (P 25 -P 75 7-23) at 3 years vs. 10 (P 25 -P 75 5 -21) at 5 years, P ¼ 0.012]. We recorded 457 deaths during follow-up. In a comprehensive multivariable Cox regression analysis, baseline QoL remained a significant prognosticator during follow-up [hazard ratio (HR) Cox for death 1.012, 95% confidence interval 1.006 -1.018, P , 0.001]. QoL monitoring showed that a score increase ≥ 10% between consecutive assessments stratified high-risk patients within the next 12 months (P ¼ 0.008). ConclusionBoth baseline and follow-up QoL monitoring were useful for patient risk stratification in a real-life HF cohort. Worse QoL may warn of a worse prognosis. Widespread QoL monitoring in routine clinical practice is recommended.--

show abstract

“…Ten trials reported a QoL benefit of medication over placebo [72,90,92,93,96,99,100,124,155,162]. A partial effect was reported in two studies [61,113].…”

Section: Pharmacological Trialsmentioning

confidence: 99%

Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review

Morgan

McGee

Shelley

2007

European Journal of Cardiovascular Prevention & Rehabilitat

View full text Add to dashboard Cite

The increasing prevalence and poor prognosis associated with heart failure have prompted research to focus on improving quality of life (QoL) for heart failure patients. Research from 1996–2005 was systematically reviewed to identify randomized controlled trials that assessed QoL in heart failure. In 120 studies, 44 were medication trials; 19 surgical/procedural interventions; and 57 patient care/service delivery interventions. Studies were summarized in terms of aim, population, QoL measures used and QoL findings. Studies used 47 different measures of QoL-generic, health-related, condition-specific, domain-specific and utility measures. Most used a single QoL measure. In 87%, a condition specific QoL measure was used, with the Minnesota Living with Heart Failure Questionnaire being the favoured assessment tool. The range of QoL measures in use poses challenges for development of cumulative knowledge. Although comparability across studies is important, this must be informed by the responsiveness of the instrument selected. As carried out in other cardiac groups, comparative evaluations of instrument responsiveness are needed in heart failure. Eur J Cardiovasc Prev Rehabil 14:589-607 © 2007 The European Society of Cardiology

show abstract

Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure Trial

Cited by 52 publications

References 19 publications

Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: The INCA study

Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: The INCA study

Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value

Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review

Contact Info

Product

Resources

About